Statins and hip fracture risk in men: a population-based case-control study

详细信息    查看全文

• 作者：Annette L. Adams ; PhD ; MPH^a ; ^{Annette.L.Adams@kp.org" class="auth_mail" title="E-mail the corresponding author} ; Jiaxiao M. Shi ; PhD^a ; Kristi Reynolds ; PhD ; MPH^a ; Reina Haque ; PhD ; MPH^a ; T. Craig Cheetham ; PharmD ; MS^a ; Aniket A. Kawatkar ; PhD^a ; Donald C. Fithian ; MD^b ; Steven J. Jacobsen ; MD ; PhD^a
• 关键词：Hydroxymethylglutaryl-CoA reductase inhibitors ; Statins ; Hip fractures ; Pharmacoepidemiology
• 刊名：Annals of Epidemiology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：25
• 期：11
• 页码：844-848
• 全文大小：238 K

文摘

To estimate the association between hydroxymethylglutaryl-CoA inhibitor (statin) use and hip fracture.

Methods

We conducted a population-based case-control study. Cases were 6774 male enrollees in a large managed care organization, aged 45 or more years, with an incident hip fracture from 1997 to 2006. Controls without fracture (n = 6774) were matched to cases on age, race, and medical center. Electronic information on pharmaceutical use was used to identify the dispensing of statins from 1991 forward.

Results

Overall, 1884 (27.8%) cases and 2150 controls (31.7%) used a statin before index date (matched odds ratio [mOR] = 0.81, 95% confidence interval [CI] = 0.74–0.87). Adjustment for comorbidity burden strengthened the magnitude of the overall association (mOR = 0.68, CI = 0.62–0.74). The adjusted association was similar across age groups but was strongest among men aged 80 years or more (mOR = 0.62, CI = 0.54–0.71) and was most pronounced in African Americans (mOR = 0.43, CI = 0.28–0.64). Greater duration of statin use did not alter the odds ratios.

Conclusions

These data add to the growing evidence of a potential protective effect of statin use on bone health. However, these results need to be replicated in a prospective study that can account for confounding by indication which may explain these findings.